Search

Yun Lin Li

from Cherry Hill, NJ
Age ~44
Get Report
Also known as:
Yun T Li, Li Yun, Yan Liu
Phone and address:
302 Valley Run Dr, Cherry Hill, NJ 08002
Related to:
Hang Ki Li, 35Li Hang, 44Ki L HangLian Li, 64
Connected to:
Ai Q Li, 64Ai H Li, 81Aida Li, 67Aijun Li, 65Aiwen Q Li, 56Aiyan Li, 61Alan Li, 80Alice Li, 46Alida Li, 59Alisha Li, 31

Yun Li Phones & Addresses

  • 302 Valley Run Dr, Cherry Hill, NJ 08002
  • 2936 Unruh Ave, Philadelphia, PA 19149 (215) 990-2089

Professional Records

Medicine Doctors

Yun Li Photo 1

Yun Y. Li

View page
Specialties:
Cardiovascular Disease
Work:
OhioHealth Heart & Vascular Physicians
171 Morey Dr STE C, Marysville, OH 43040
(937) 644-4441 (phone), (937) 642-0302 (fax)
Education:
Medical School
Henan Med Univ, Zhengzhou City, Henan, China
Graduated: 1985
Procedures:
Cardiac Stress Test
Cardioversion
Echocardiogram
Continuous EKG
Electrocardiogram (EKG or ECG)
Pacemaker and Defibrillator Procedures
Conditions:
Heart Failure
Acute Myocardial Infarction (AMI)
Angina Pectoris
Aortic Aneurism
Aortic Regurgitation
Languages:
Chinese
English
Spanish
Description:
Dr. Li graduated from the Henan Med Univ, Zhengzhou City, Henan, China in 1985. Dr. Li works in Marysville, OH and specializes in Cardiovascular Disease. Dr. Li is affiliated with Memorial Hospital and OhioHealth Doctors Hospital.

Business Records

Name / Title
Company / Classification
Phones & Addresses
Yun Li
ANNLEE CARE HOMES, LLC

Publications

Isbn (Books And Publications)

Parallel Processing in a Control Systems Environment

View page
Author

Yun Li

ISBN #

0136515304

Wikipedia

Li Yun

View page

Li Yun () (died 887), imperial princely title Prince of Xiang (), was a pretender to the throne of the Chinese dynasty Tang Dynasty, who briefly, under the ...

Li Yun (Water Margin)

View page

Li Yun is a fictional character in the Water Margin, one of the Four Great Classical Novels of Chinese literature. He ranks 97th of the 108 Liangshan heroes and 61st

Us Patents

Substituted Cyclic Hydroxamates As Lnhibitors Of Matrix Metalloproteinases

View page
US Patent:
20080167288, Jul 10, 2008
Filed:
Feb 15, 2008
Appl. No.:
12/070310
Inventors:
Yun Long Li - Wilmington DE, US
Jincong Zhuo - Marcus Hook PA, US
David Burns - Philadelphia PA, US
Wanqing Yao - Kennett Square PA, US
Ravi Kumar Jalluri - Avondale PA, US
Assignee:
Lncyte Corporation - Wilmington DE
International Classification:
A61K 31/397
C07D 221/00
A61K 31/4523
C07D 295/00
A61K 31/5377
A61P 17/00
A61P 37/00
A61P 29/00
A61K 31/496
C07D 209/02
A61K 31/403
C07D 213/02
A61K 31/44
C07D 221/02
A61K 31/435
C07D 241/36
A61K 31/498
C07D 207/00
A61K 31/541
A61P 9/00
A61K 31/40
C07D 215/00
A61K 31/47
A61P 35/00
A61P 19/02
C07D 205/02
US Classification:
51421018, 546194, 514318, 544129, 5142355, 546187, 514316, 544360, 51425301, 546208, 514326, 548469, 514415, 546314, 514354, 546112, 514299, 544349, 514249, 548530, 514423, 546152, 514314, 544121, 5142358, 548953, 544 60, 5142278
Abstract:
The present invention provides compounds of the formula:its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

Compositions And Methods For Enhancing Odorant Receptor Activity

View page
US Patent:
20130004983, Jan 3, 2013
Filed:
Dec 6, 2010
Appl. No.:
13/513600
Inventors:
Hiroaki Matsunami - Durham NC, US
Yun Li - Philadelphia PA, US
International Classification:
C12N 5/071
C12Q 1/02
US Classification:
435 29, 435369
Abstract:
The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2 M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

Compositions And Methods For Enhancing Odorant Receptor Activity

View page
US Patent:
20210139986, May 13, 2021
Filed:
Dec 31, 2020
Appl. No.:
17/139266
Inventors:
- Durham NC, US
Yun Li - Philadelphia PA, US
International Classification:
C12Q 1/6881
C07K 14/705
Abstract:
The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

Compositions And Methods For Use In Combination For The Treatment And Diagnosis Of Autoimmune Diseases

View page
US Patent:
20200080152, Mar 12, 2020
Filed:
Aug 20, 2019
Appl. No.:
16/545469
Inventors:
- Philadelphia PA, US
Yun Rose Li - Philadelphia PA, US
Brendan Keating - Philadelphia PA, US
International Classification:
C12Q 1/6883
Abstract:
This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

Compositions And Methods For Enhancing Odorant Receptor Activity

View page
US Patent:
20190002980, Jan 3, 2019
Filed:
Sep 10, 2018
Appl. No.:
16/126581
Inventors:
- Durham NC, US
Yun Li - Philadelphia PA, US
International Classification:
C12Q 1/6881
C07K 14/705
Abstract:
The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

Compositions And Methods For Enhancing Odorant Receptor Activity

View page
US Patent:
20170283872, Oct 5, 2017
Filed:
Apr 3, 2017
Appl. No.:
15/477873
Inventors:
- Durham NC, US
Yun Li - Philadelphia PA, US
International Classification:
C12Q 1/68
C07K 14/705
Abstract:
The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

Compositions And Methods For Use In Combination For The Treatment And Diagnosis Of Autoimmune Diseases

View page
US Patent:
20170051351, Feb 23, 2017
Filed:
Aug 19, 2016
Appl. No.:
15/242091
Inventors:
- Philadelphia PA, US
Yun Rose Li - Philadelphia PA, US
Brendan Keating - Philadelphia PA, US
International Classification:
C12Q 1/68
Abstract:
This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

Methods Of Treating Autoimmune Conditions In Patients With Genetic Variations In Dcr3 Or In A Dcr3 Network Gene

View page
US Patent:
20170051352, Feb 23, 2017
Filed:
Aug 19, 2016
Appl. No.:
15/242210
Inventors:
- Philadelphia PA, US
Charlly Kao - Philadelphia PA, US
Christopher Cardinale - Philadelphia PA, US
Rahul Pandey - Philadelphia PA, US
Yun Rose Li - Philadelphia PA, US
International Classification:
C12Q 1/68
C07K 16/24
C12N 15/113
Abstract:
The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TL1A, and FasL, such as anti-LIGHT, anti-TL1A, and anti-FasL antibodies, or inhibitors of the non-canonical NF-κB pathway.
Control profile
Yun Lin Li from Cherry Hill, NJ, age ~44 Get Report